Pfizer for Professionals

Print this page | Cancel

New user?

Why Register?

----------------------------------------------

Returning user?

----------------------------------------------

Forgot Password?

Registration FAQs

Patient Education Materials

Patient Assistance Programs

Clinical Trials

Pipeline

Pfizer Contacts

Pfizer Medical Information
(Search Medical Responses)

WyethHCP.com
(Access Wyeth for Professionals)

Explore Other Online Resources

ppn-vr-sso-links.htm

To report an adverse event or to speak to a member of Pfizer Medical Information, please call 1-800-438-1985

Product Centers



		When oral therapy is not feasible, and the strength, dosage form and route of administration of the drug reasonably lend the preparation to the treatment of the condition, SOLU-MEDROL Sterile Powder is indicated for intravenous or intramuscular use in the following conditions: Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Epicondylitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis Acute and subacute bursitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Severe psoriasis Exfoliative dermatitis Mycosis fungoides Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Drug hypersensitivity reactions Contact dermatitis Urticarial transfusion reactions Atopic dermatitis Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) Serum sickness Seasonal or perennial allergic rhinitis Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Sympathetic ophthalmia Iritis, iridocyclitis Anterior segment inflammation Chorioretinitis Allergic conjunctivitis Diffuse posterior uveitis and choroiditis Allergic corneal marginal ulcers Optic neuritis Keratitis Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis Hematologic Disorders Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Congenital (erythroid) hypoplastic anemia Secondary thrombocytopenia in adults Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Nervous System Acute exacerbations of multiple sclerosis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement

SOLU-MEDROL Safety Information

Important Safety Information

SOLU-MEDROL Sterile Powder is contraindicated in premature infants because of a risk of fatal gasping syndrome. SOLU-MEDROL is also contraindicated in systemic fungal infections and patients with known hypersensitivity to the product and its constituents.

Corticosteroids may mask some signs of infection, and new infections may appear during their use, especially in patients with immune deficiency. Prolonged use of corticosteroids may produce ocular damage. An acute myopathy has been observed with the use of high doses of corticosteroids. Average and large doses of corticosteroids can cause elevation of blood pressure, salt and water retention, and increased excretion of potassium. There are reports of cardiac arrhythmias and/or circulatory collapse and/or cardiac arrest. As with all corticosteroids, SOLU-MEDROL has been associated with fluid retention and electrolyte abnormalities, hypertension, hyperglycemia, osteoporosis, dermatologic disorders, myopathy, ophthalmic problems, and growth arrest.

Please see full prescribing information.

SOLU-MEDROL^® (methylprednisolone sodium succinate)

solu_medrol_safety_information.htm

SOLU-MEDROL^® (methylprednisolone sodium succinate)

Full Prescribing Information

Select the e-mail communications you would like to receive.*

Pain & Inflammation Alerts

To manage your other communication preferences, visit My Profile.

* Registration required.